Drug Profile
Research programme: sigma-1 receptor property enhancers - Esteve
Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator ESTEVE
- Class Analgesics; Small molecules
- Mechanism of Action Sigma-1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Pain in Spain
- 24 Jul 2019 Preclinical development for the programme is still ongoing Spain (ESTEVE pipeline, July 2019)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Pain in Spain